New Luth Research Study: AI Has Not Replaced the Patient Journey, It Has Reconfigured It

Luth Research found that roughly 80% of patients using AI for health information also use other sources, with 60% turning to health-information websites as their leading companion source. In a study tracking 1,538 consumers and surveying 537 patients, AI was primarily used for quick, plain-language exploration, while trusted health sites remained central to appointment preparation and treatment decisions. Hybrid researchers spent three times longer researching chronic conditions than AI-only users, supporting the view that AI is supplementing rather than displacing established digital health-information platforms.

Analysis

The investable implication is not broad healthcare-AI monetization, but a reshaping of the patient-acquisition funnel. AI may reduce low-intent search traffic while increasing the conversion value of users who reach clinically credible destinations after an initial query. Public companies with direct-to-consumer care funnels—HIMS, TDOC and DOCS—could benefit only if they can establish authoritative, cited content and convert better-informed users; otherwise AI interfaces become another paid/referral gatekeeper and raise customer-acquisition costs.

The structural beneficiary is likely the platform controlling AI referrals and patient intent data, principally GOOGL, rather than content publishers. Over 6-18 months, health publishers without differentiated clinical validation, provider networks, or proprietary patient tools face traffic and ad-yield pressure even if aggregate health-information consumption rises. The study is directionally useful but not independently sufficient to underwrite revenue forecasts: it does not establish referral volumes, conversion rates, or whether AI answers substitute for monetizable pageviews.

Consensus may be too quick to frame AI as an outright traffic destroyer for health-information businesses. Chronic-condition users are high-frequency, high-LTV cohorts, and repeated validation needs can preserve destination-site engagement; the key distinction will be trusted transactional utility—appointment booking, treatment navigation, adherence tools—not static explanatory content. A near-term catalyst is disclosure from GOOGL, HIMS or TDOC on AI-driven referral mix, conversion, and CAC; absent that evidence, this is a watch item rather than a standalone trade.

Key Decisions for Investors

• No immediate directional trade on the study alone; set an alert for HIMS and TDOC quarterly disclosures showing AI/referral-channel conversion or CAC movement. A sustained CAC increase without offsetting conversion improvement would be bearish for both within 1-3 quarters.
• Monitor GOOGL versus health-content-dependent digital-ad peers for evidence that AI search captures incremental health-query monetization. Consider a long GOOGL / short broad digital-content exposure only after verifiable referral-share or search-ad pricing data confirms platform value capture.
• For HIMS, treat improvement in repeat revenue and marketing efficiency—not AI-content announcements—as the confirmation trigger. A material CAC increase or deceleration in subscriber growth would falsify the view that AI-assisted research produces higher-intent patient demand.
• Avoid extrapolating the finding to managed-care or pharmaceutical earnings: treatment decisions remain constrained by coverage, provider access, formularies, and clinical pathways, so consumer research behavior is unlikely to alter near-term utilization or drug demand materially.